Navigation Links
TheraTears Economy Size

ProductsTheraTears Economy Size
Company Advanced Vision Research, Inc.
Item TheraTears Economy Size
Features Finally, an eye drop for dry eye that really works!

18 years of clinical research, testing and development by an eye physician focused on one goal: to develop an effective medication for dry eye. The result: a medical breakthrough called TheraTears.

Dry eye irritation and disease is a result of loss of water from the tears on the eye surface. TheraTears helps put back the lost water so that it not only wets but also rehydrates dry eyes. In addition, the tears are an electrolyte solution specially designed to protect the eye surface. With TheraTears we replicated and patented the electrolyte balance of the human tear film.

So by lubricating, rehydrating and protecting the eye, TheraTears provides soothing, long-lasting and cumulative dry eye relief that really works!

Description TheraTears in a bottle becomes preservative-free on eye contactits patented preserving ingredient turns into oxygen and water on eye contact. It is designed for eyes with mild to moderate dryness or eyes that need occasional or maintenance treatment. Now you can have the benefits of a preservative-free solution, and use only the drops you need!
Info Advanced Vision Research, Inc.
Customer Service: (800) 579-8327
Web site: http://theratears.com

Related medicine products :

1. Preservative-Free TheraTears
2. TheraTears in a bottle
3. TheraTears Contact Lens Comfort Drops
4. Preservative-Free TheraTears Liquid Gel
5. Precision Economy Incubators 3EM
6. Precision Economy Incubators 5EM
7. Precision Economy Incubators 2EG
8. Precision Economy Incubators 3EG
9. Precision Economy Incubators 5EG
10. Schiotz Tonometer Certified Calibration (Economy Model)
11. Economy
Breaking Medicine Technology:Hand Surgeons Take Ethics into Their Own Hands 2Hand Surgeons Take Ethics into Their Own Hands 3Hand Surgeons Take Ethics into Their Own Hands 4Berger & Montague, P.C., Files Class Action Against Hemispherx Biopharma, Inc. Extending the End of the Class Period to December 1, 2009, When the Company Announced That the FDA Found No Evidence of Efficacy of Its Drug 2Berger & Montague, P.C., Files Class Action Against Hemispherx Biopharma, Inc. Extending the End of the Class Period to December 1, 2009, When the Company Announced That the FDA Found No Evidence of Efficacy of Its Drug 3FDA Grants Cequent IND - Clears Way for First-Ever Clinical Trial of Orally Delivered RNAi Therapeutic: CEQ508, a tkRNAi Drug Candidate in Oncology 2FDA Grants Cequent IND - Clears Way for First-Ever Clinical Trial of Orally Delivered RNAi Therapeutic: CEQ508, a tkRNAi Drug Candidate in Oncology 3FDA Grants Cequent IND - Clears Way for First-Ever Clinical Trial of Orally Delivered RNAi Therapeutic: CEQ508, a tkRNAi Drug Candidate in Oncology 4H1N1 Focus of California Hospital Association Disaster Planning Conference 57101 1H1N1 Focus of California Hospital Association Disaster Planning Conference 57101 2H1N1 Focus of California Hospital Association Disaster Planning Conference 57101 3Intelligent Design Film to Premiere at Sam Noble Oklahoma Museum of Natural History Sept 29 14029 1Intelligent Design Film to Premiere at Sam Noble Oklahoma Museum of Natural History Sept 29 14029 2PolyOne Presented with Frost 26 Sullivan Medical Product Award 57096 1PolyOne Presented with Frost 26 Sullivan Medical Product Award 57096 2